Alcon ACL
-
Execution Blurring Novartis's Potential
… while core operating income fell 8%. The two relative bright spots for the first quarter were the pharmaceuticals and Alcon businesses. Pharma sales rose 2% (or 3% in constant Complete Story »
-
Novartis AG NVS Q1 2012 Earnings Call Transcript
… call. We've got on the Novartis end, Jon Symonds, CFO; David Epstein, Head of Pharma; Kevin Buehler, Head of the Alcon business; Jeff George, Head of Sandoz; Andrin Oswald, Head of VnD; George Gunn, Head of Animal Health; and Brian …
-
Nestle Scores in Deal to Acquire Pfizer's Nutrition Business
… growth opportunity is reflected in the rich multiple Nestle is paying for the investment. When Nestle sold its stake in Alcon to Novartis NVS for $28 billion pretax, we argued that it should invest the cash in extending its footprint in emerging …
-
New Morningstar Analyst Report - Novartis AG
… next several years.The addition of Alcon brings strong exposure to the second ..... additional debt needed to fund the Alcon acquisition, we expect Novartis will ..... competitors. Further, the acquisition of Alcon in 2011 greatly boosts Novartis' consumer …
-
Novartis AG NVS Q4 2011 Earnings Call Transcript
… the CFO; and then we have a number of the Division Heads here David Epstein, Head of Pharma; Kevin Buehler, Head of Alcon Division; Jeff George, Head of Sandoz; Andrin Oswald, Head of Vaccines and Diagnostics; George Gunn, Head of Animal …
-
Novartis Misses, Plans Job Cuts
… however slightly down sequentially as well as below the Zacks Consensus Estimate of $15.1 billion. The Pharmaceuticals, Alcon and Sandoz divisions were all down sequentially while the Consumer Health segment remained flat quarter over quarter. Novartis …
-
Novartis unit Alcon faces U.S. health fraud probe
Oct 25 (Reuters) - Novartis's recently acquired eyecare business Alcon is facing a U.S. government investigation into alleged healthcare fraud, the Swiss drugmaker said on Tuesday.
-
Novartis AG NVS Q3 2011 Earnings Call Transcript
… Joining me on the Novartis end are Jon Symonds, CFO; David Epstein, the Head of Pharma Division; Kevin Buehler, Head of Alcon ; Jeff George, Head of Sandoz; and Andrin Oswald, Head of Vaccines and Diagnostics. Click here for the full transcript …
-
UPDATE 2-Novartis sees strong growth at Alcon unit
* Sees Alcon growing in high-single to low-double digit range
-
Novartis sees $350 mln in synergies from Alcon buy
ZURICH, Sept 13 (Reuters) - Novartis AG is now aiming for cost synergies from its recently acquired eyecare group Alcon of $350 million per year by 2013, the Swiss drugmaker said ahead of an investor day in London.